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Abstract
This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in
association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016
in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based
agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders,
including members of the FDA, leading academic institutions and industrial drug developers, to consider topics
relevant to the future of cancer immunotherapy.
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Meeting Summary
In the wake of an unprecedented number of U.S. Food
and Drug Administration (FDA) approvals for cancer
immunotherapy agents, particularly immune checkpoint
inhibitors, the field is poised for further advancement.
An associated program of SITC’s 31st Annual Meeting in
November 2016, the ‘New Cancer Immunotherapy
Agents in Development’ session was organized through
collaboration between the SITC Annual Program Com-
mittee and the SITC Industry Committee. The goal of
the program was to provide an opportunity to address
challenges faced by experts in industry, government, and
academia who are working to deliver better outcomes
for patients with cancer. The recent focus on combin-
ation therapies has increased the complexity of this task
and raises important mechanistic considerations as to
how each additional agent affects the underlying biology
of the cancer as well as the immune system of the
individual. Moreover, logistical aspects of the application
of cancer immunotherapy such as the use of biomarkers,
optimal duration of treatment, determining the most ap-
propriate clinical endpoints, and how many drugs to use
in combination have yet to be determined.
To facilitate the conversation about drugs on the can-
cer immunotherapy horizon, program co-chairs Adrian
Bot, MD, PhD (Kite Pharma, Inc.), Daniel S. Chen, MD,
PhD (Genentech/Roche), Roger D. Dansey, MD (Merck
& Co., Inc.), Ramy Ibrahim, MD (The Parker Institute
for Cancer Immunotherapy), and Salil Patel, PhD (Bris-
tol-Myers Squibb) divided the program into three ses-
sions: (1) Clinical New Agents in Development; (2) Pre-
Clinical New Agents in Development; and (3) Strategic
Considerations of Combinations and Biomarkers in New
Agent Development. The third session closed the pro-
gram with an extended panel discussion featuring expert
representatives from clinical, translational, and govern-
ment backgrounds to provide unique perspectives on
the development of cancer immunotherapeutics. This
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report summarizes key topics presented by the invited
speakers and panel discussants.
Clinical New Agents in Development
Elizabeth Evans, PhD (Vaccinex, Inc.) presented pre-
clinical data supporting the combination of anti-
semaphorin 4D (SEMA4D) with ipilimumab (anti-
CTLA-4) or anti-PD-1/PD-L1 agents. SEMA4D is a
guidance molecule capable of regulating the migration
and differentiation of cells expressing its receptor.
Expressed on tumor cells and immune cells at the inva-
sive tumor margin, SEMA4D inhibits the migration of
antigen presenting cells (APC) and prevents immune
cells from infiltrating the tumor. Antibody blockade of
SEMA4D facilitated the ability of functional tumor-
specific CD8+ T cells and dendritic cells (DC) to migrate
into the tumor, while reducing the number of immuno-
suppressive cells such as regulatory T cells (Treg) and
myeloid-derived suppressor cells (MDSC) within the
tumor microenvironment (TME). Single agent anti-
SEMA4D shifted the balance of immune activity in the
TME and significantly delayed tumor growth, but in-
duced a relatively low frequency of complete tumor re-
gression in some preclinical models. In contrast, when
administered in combination with immune checkpoint
inhibitors, anti-SEMA4D significantly enhanced the ac-
tivity of anti-CTLA-4 and anti-PD-1 therapies [1]. The
humanized IgG4 anti-SEMA4D was well-tolerated in
phase I trials (NCT01313065) [2] and phase Ib/II studies
of anti-SEMA4D in combination with anti-PD-L1 for
the treatment of non-small cell lung cancer (NSCLC)
are planned in collaboration with EMD Serono. Add-
itional phase Ib/II studies of anti-SEMA4D in combin-
ation with anti-PD-L1 and/or anti-CTLA-4 for
treatment of melanoma and head and neck squamous
cell carcinoma (HNSCC) are anticipated.
Idera’s Oncology Lead, Mark Cornfeld, MD, MPH,
presented an overview of the mechanism of action of
IMO-2125, an investigational intratumoral toll-like re-
ceptor nine (TLR9) agonist that can modulate the TME
to enhance anti-tumor immunity. IMO-2125 is specific-
ally designed to activate TLR9, an immune signaling pro-
tein. Through TLR9, IMO-2125 activates DC and
induces an innate immune response in the TME. The
subsequent recruitment and activation of tumor infiltrat-
ing lymphocytes (TIL) and other immune cells enhances
antigen presentation and T cell expansion. In previously
completed clinical trials in the setting of hepatitis C in-
fection, subcutaneous administration of IMO-2125 was
generally well tolerated and had pharmacologic activity.
Idera subsequently conducted extensive preclinical re-
search in multiple animal models of cancer that showed
intratumoral IMO-2125 enhanced the anti-tumor activ-
ity of checkpoint inhibitors. Data from these clinical and
nonclinical studies supported the initiation of a phase I/
II clinical trial of intratumoral IMO-2125 in combin-
ation with ipilimumab in patients with metastatic melan-
oma refractory to prior anti-PD-1 therapy. Preliminary
data from this trial were first presented at the SITC
2016 Annual Meeting [3]. Results showed that escalating
doses of IMO-2125 in combination with ipilimumab
were well tolerated with a maximum tolerated dose not
yet identified. DC maturation was observed in tumor bi-
opsies obtained 24 h after the first IMO-2125 treatment
and before ipilimumab treatment was initiated. In
addition, immunologic activity in responding patients in-
cluded increased T cell infiltration in untreated tumors.
A new approach, described by Edward Cha, MD, PhD
(Genentech), sought to combine the efficacy of targeted
therapies with the durable responses seen following im-
mune checkpoint inhibition therapy. The rationale for
combining the selective MEK1 and MEK2 inhibitor
cobimetinib with the PD-L1 blocking drug atezolizumab
arose from the observation that MEK inhibition has
positive immunomodulatory effects including intratu-
moral T cell accumulation and upregulation of MHC
class I, potentially promoting antigen presentation and
tumor immunogenicity. Moreover, the combination of
MEK inhibition and anti-PD-L1 led to enhanced efficacy
and durable regression in multiple tumor models [4].
Tumor samples from the phase Ib study of the combin-
ation of cobimetinib and atezolizumab in patients with
solid tumors reiterated the T cell and MHC class I ef-
fects of MEK inhibition seen in pre-clinical models, and
preliminary data demonstrated a manageable safety pro-
file in the population of metastatic colorectal cancer
(CRC) patients. Of the CRC patients, four had con-
firmed partial responses (PR; per RECIST v1.1), three of
which had known microsatellite-stable tumors, and re-
sponses for two of those patients were ongoing beyond
15 months. The durability of this treatment combination
was also demonstrated in a cohort of patients with
metastatic melanoma of cutaneous and mucosal ori-
gin. Among the 20 patients, there were nine (45%)
confirmed PR with a median duration of response of
15 months [5].
In another discussion of novel combination strategies,
the Chief Medical Officer for Celldex Therapeutics, Inc.,
Thomas Davis, MD, led with the assertion that it will be
necessary to influence multiple steps of the immune re-
sponse in order to maximize the clinical benefits of im-
munotherapy, a sentiment that was echoed by several
presenters throughout the program. Towards that goal, a
number of agents in the Celldex pipeline aim to impact
the recruitment and activation of dendritic cell (DC) or
T cells. Examples of these immunotherapeutics include
CDX-1401, CDX-301, and varlilumab. CDX-1401 is an
antibody fusion protein that delivers antigen to DC by
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targeting DEC-205, which can efficiently internalize and
present any antigen attached to the antibody. Phase I
studies of this antigen delivery system using NY-ESO-1
as the fusion antigen given in combination with poly-
ICLC showed excellent tolerability and generated good
immune responses. The establishment of a tumor-
specific immune response significantly increased patient
responsiveness to subsequent immune checkpoint block-
ade in 7/7 (100%) patients with NY-ESO-1+ tumors. The
CDX-1401 vaccine is being tested in combination with
CDX-301 (Flt3L), a potent expander of DC progenitors
[6], via collaboration with the Cancer Immunotherapy
Trials Network (CITN). Varlilumab is another Celldex
product candidate that was mentioned briefly. This
CD27 agonist is a potent lymphocyte activator with es-
sentially no associated toxicity and is currently being in-
vestigated in different combinations, including with
CDX-1401 and immune checkpoint inhibitors.
Rom S. Leidner, MD (Earle A. Chiles Research Institute)
discussed the vital role that natural killer (NK) cells play
in immune surveillance and control of tumor growth. NK
cell activation is regulated in part by killer cell
immunoglobulin-like receptors (KIR), predominantly
expressed on NK cells as well as some CD8+ T cells. Liri-
lumab is a fully human IgG4 monoclonal antibody that
targets inhibitory KIR, thereby promoting NK cell antitu-
mor activity. Potentiating an antitumor immune response
through blocking inhibitory KIR may complement other
immuno-oncology therapies that enhance T cell activity,
such as the immune checkpoint inhibitors nivolumab
(anti-PD-1) and ipilimumab. Dr. Leidner presented safety
data from two phase I studies of lirilumab in combination
with nivolumab (CA223-001; NCT01714739) or ipilimu-
mab (CA223-002; NCT01750580) in patients with ad-
vanced solid tumors. In the dose-escalation and cohort-
expansion phases of the ongoing CA223-001 study, 159
patients were treated with lirilumab 0.1 to 3 mg/kg every
4 weeks (Q4W) plus nivolumab 3 mg/kg Q2W. In the
dose-escalation phase of CA223-002, 22 patients were
treated with lirilumab 0.1 to 3 mg/kg Q3W plus ipilimu-
mab 3 mg/kg Q3W. Both combination regimens were
manageable. The safety profile of lirilumab plus nivolumab
or ipilimumab appeared consistent with prior reports of
nivolumab or ipilimumab monotherapy, with the excep-
tion of low-grade infusion-related reactions with lirilumab
plus nivolumab; these events were manageable, and most
occurred after the first dose. Further evaluation of lirilu-
mab plus nivolumab is ongoing.
Another approach targeting NK cells was presented by
Adi Diab, MD (The University of Texas MD Anderson
Cancer Center). NKTR-214 is a CD122-biased agonist
and is the only cytokine immunotherapy that preferen-
tially expands both effector CD8+ T cells and NK cells
within the TME. Preclinical data show tumor growth
suppression in multiple tumor models when used as a
single agent or in combination. A phase I/II trial was ini-
tiated to evaluate the safety and efficacy of NKTR-214
and to assess immune changes in the TME. Patients with
locally advanced or metastatic solid tumors were admin-
istered NKTR-214 IV q2-q3 weeks as a 15 min IV infu-
sion starting at a dose of 0.003 mg/kg. As of November
9, 2016, 25 patients had received treatment with NKTR-
214 in 5 different dose cohorts ranging from 0.003 mg/
kg-0.012 mg/kg. The median number of prior anticancer
therapies was two and 60% of patients had received at
least one prior immunotherapy agent. One patient expe-
rienced dose-limiting toxicities (DLT) (Grade 3 syncope
and hypotension) at 0.012 mg/kg. No immune-related
adverse events (AE) or capillary leak syndrome were ob-
served at any dose. There have been no grade 4 toxicities
or deaths on study; 4/25 (16%) experienced a Grade 3
treatment emergent AE and 3/25 (12%) experienced
Grade 3 hypotension. All cases of hypotension were rap-
idly reversed with fluids and no patient discontinued
treatment as a result. In all patients evaluated, analysis
of blood samples showed concordant increases in Ki67+
immune cells, PD-1+ CD8+ T cells, and NK cells 8 days
after a single dose of NKTR-214. Flow cytometry enu-
meration and/or immunohistochemistry (IHC) revealed
an up to 10-fold increase from baseline in CD8+ T cells
and NK cells in the TME, with minimal changes to Treg.
Demonstrating encouraging evidence of single agent ac-
tivity in heavily pre-treated patients, 7/18 (39%) patients
had radiographic tumor reductions and one patient with
renal cell carcinoma (RCC) had an unconfirmed partial
response (PR) at the initial 6 or 8-week scan.
Closing the Clinical session, Patrick Soon-Shiong, MD
(NantWorks/NantKwest) discussed a novel line of off-
the-shelf activated NK cells called NK-92. This platform
makes use of NK cells as key rapid-responders to more
efficiently target malignant cells and has moved from
phase I to phase II trials. Specifically, the NK-92 cell line
is armed with activation receptors, but lacks inhibitory
receptors and can be further engineered to target tumor
cells in a customizable way. When made to express the
high affinity Fc receptor CD16, NK-92 can help mediate
antibody killing in combination with so-called “chimeric
antigen receptors (CAR) in a bottle” such as anti-HER2,
anti-CD20, and anti-EGFR. Alternatively, NK-92 can be
made to bind directly to target antigens via expression
of CAR. Data from studies of the high affinity CD16-
expressing NK-92 in combination with the IgG1-based
agents trastuzumab, pertuzumab, cetuximab, and avelu-
mab for the treatment of breast cancer and lung cancer,
have demonstrated the impressive tumoricidal activity of
the high affinity NK-92 technology. Additionally, a tar-
geted version of single agent NK-92 was given to a heav-
ily pretreated patient with advanced Merkel cell
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carcinoma and a response was noted within 14 days of
NK-92 infusion, with radiological CR by day 171. Using
this platform, pre-clinical investigations of NK-92/5.28.z
cells targeting ErbB2 have been shown to induce second-
ary responses in a murine model of glioma [7], which
provides an encouraging framework from which to move
into clinical trials in the setting of highly metastatic
disease.
Pre-Clinical New Agents in Development
Bryan A. Irving, PhD (CytomX Therapeutics, Inc.)
kicked off the Pre-Clinical session with a presentation
on T cell-engaging bispecific antibodies (TCB), which
represent a highly potent vehicle for directing the activ-
ity of cytotoxic T cells against tumors, including tumors
that lack sufficient mutations to generate tumor-specific
immunity. TCB have shown clinical activity in
hematologic malignancies but their development for
non-hematologic cancers has been challenging, due in
part to toxicities that result from interaction with
healthy cells expressing the target antigen. Therefore,
new approaches are needed that enable the use of TCB
without on-target damage to normal tissues. CytomX
has developed a new class of antibodies, proteolytically
activatable antibody prodrugs called Probody™ therapeu-
tics that are designed to widen the therapeutic window
by minimizing interaction with normal tissue and maxi-
mizing interaction with tumor tissue. Probody therapeu-
tics are “masked” to reduce binding to antigen in healthy
tissue, but can become “unmasked” in the TME by
tumor-specific protease activity. CytomX has demon-
strated the ability of a Probody T cell-engaging bispecific
(Pb-TCB) targeting CD3 and epidermal growth factor re-
ceptor (EGFR), to provide equivalent anti-tumor activity
in NSG (NOD scid gamma) mice to its corresponding
unmasked antibody bispecific, while increasing the max-
imum tolerated dose and exposure by >30-fold and 300-
fold, respectively, in cynomolgus monkeys. By localizing
their activity to the TME, Pb-TCB have the potential to
expand clinical opportunities for T cell-engaging bispeci-
fic therapies in solid tumors, which are currently limited
by on-target toxicities.
Shane A. Olwill, PhD (Pieris Pharmaceuticals GmbH),
presented data on CD137 (4-1BB), a key costimulatory
immunoreceptor and a highly promising therapeutic tar-
get in cancer. To overcome limitations of current mono-
clonal antibody (mAb)-based approaches which target
CD137 monospecifically, a CD137/HER2 bispecific
(PRS-343) was designed to promote CD137 clustering
by bridging CD137-positive T cells with HER2-positive
tumor cells, thereby providing a potent costimulatory
signal to tumor antigen-specific T cells. PRS-343 was
generated as a genetic fusion of a CD137-specific Antic-
alin® protein to an IgG4 variant of trastuzumab. PRS-343
was found to efficiently activate T cells ex vivo in the
presence of HER2-positive cells. In vivo proof of concept
studies showed that PRS-343 led to strong tumor growth
inhibition in a dose-dependent manner, compared to
treatment with isotype control. Tumor response was ac-
companied by a significantly higher frequency of hCD45
+ TIL as determined by IHC. T cell phenotyping indi-
cated that the increase in TIL frequency was due to ex-
pansion of CD3+ CD8+ T cells, while CD4+
lymphocytes remained at a low frequency. PRS-343 was
shown to elicit potent costimulatory T cell engagement
of the immunoreceptor CD137 in a HER2-dependent
manner, and to display dual activity in vivo, based on
monospecific HER2-targeting and bispecific, tumor-
localized costimulation of CD137. Compared to
known CD137-targeting antibodies in clinical develop-
ment, PRS-343 may provide more localized activation
of the immune system with higher efficacy and re-
duced peripheral toxicity. The positive functional data
of PRS-343 support investigation of its anti-cancer ac-
tivity in clinical trials.
Thomas W. Dubensky Jr., PhD (Aduro Biotech) dis-
cussed a personalized therapy in development, known as
pLADD, which is live, attenuated double-deleted Listeria
monocytogenes (LADD) that has been engineered to en-
code multiple tumor-specific neoantigens. The LADD
platform is an attractive approach for personalized im-
munotherapy due to the rapid construction, manufac-
ture, and release of pLADD clinical strains. Moreover, a
clinical safety and efficacy profile has been established in
over 400 patients and the robust activation of innate im-
munity and TME remodeling has been demonstrated in
preclinical models and in patients. The Aduro Biotech
group partnered with Hanlee P. Ji, MD, PhD (Stanford
University), a physician-scientist focused on colorectal
cancer (CRC) and has developed proprietary computa-
tional methods for neo-epitope identification [8]. In pre-
clinical models, novel methods were developed to site-
specifically integrate expression cassettes into the
pLADD chromosome, resulting in the robust expression,
secretion and processing of approximately 25 encoded
neoepitopes into the MHC class I presentation pathway
of infected antigen presenting cells. Subsequent studies
using tumor-bearing mice demonstrated that a pLADD
strain expressing tumor-specific neoepitopes from mur-
ine MC38 tumor cells could induce robust CD8+ T cell
responses specific for encoded neoepitopes, but not
against native sequences. This personalized approach
was highly effective in combination with PD-1 blockade.
An Investigational New Drug Application has been
allowed, and a phase I trial will be initiated in 2017 to
evaluate the safety and immunogenicity of pLADD in
patients with cancers of the gastrointestinal tract, focus-
ing on microsatellite stable (MSS) CRC, an indication in
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which responses with immune checkpoint inhibition
monotherapy have been poor.
The presentation by David Tuck, MD (Curis) focused
on CA-170. This small molecule is an orally bioavailable
antagonist of the PD-L1, PD-L2, and VISTA/PD-1H im-
mune checkpoint pathways and is currently undergoing
phase I clinical testing. CA-170 was developed through a
rational design and screening strategy that identified
small molecules capable of antagonizing T cell suppres-
sion mediated by PD-L1, PD-L2, and VISTA/PD-1H in
vitro. CA-170 exhibits potent immune rescue activity,
comparable to that of PD-1 or VISTA/PD-1H blocking
antibodies in functional assays. CA-170 does not exhibit
off-target activity against CTLA-4, LAG-3, BTLA path-
ways, or the B7/CD28 pathway. In immune-competent
mice, orally administered CA-170 inhibits the growth of
syngeneic tumors, enhances peripheral T cell activation,
and promotes the activation of tumor infiltrating CD8+
T cells in a dose-dependent manner. Pre-clinical safety
studies of CA-170 in rodents and non-human primates
showed no signs of toxicity when dosed orally up to
1000 mg/kg for 28 consecutive days. CA-170 exhibits an
oral bioavailability of approximately 40% and <10% in
mouse and cynomolgus monkey, respectively, with re-
spective plasma half-lives ranging from 0.5 h to 3.25-
4.0 h. The clinical pharmacokinetic profile is similar to
non-clinical and human exposure and appears to be
highly predictable on oral dosing. CA-170 leads to in-
creases in activated CD8+ T cells in the peripheral blood
of cancer patients following oral dosing, supporting its
continued clinical development.
Frederic Triebel, MD, PhD (Prima Biomed) shared
pre-clinical data for IMP321, which is a LAG-3Ig fusion
protein that binds to major histocompatibility complex
(MHC) class II molecules on the surface of APC and
triggers activation of APC and CD8+ T cells known to
mediate tumor recognition and killing. IMP321 induces
more Tc1 subset differentiation and IFN-γ compared to
other APC activators, such as CD40L, or TLR agonists
that induce immunosuppressive IL-10 production [9]. In
the clinic, IMP321 has been used at low doses as an ad-
juvant to cancer vaccines [10–12] and at higher doses as
an APC activator to boost the DC network loaded with
tumor antigens after first-line chemotherapy [13]. The
randomized, double blind, placebo-controlled AIPAC
(ACTive Immunotherapy PAClitaxel) phase IIb registra-
tion trial has now commenced in the EU (enrolling 241
patients) and will test IMP321 combined with weekly
paclitaxel in a first-line setting in hormone receptor-
positive metastatic breast cancer (NCT02614833). Indu-
cing more TIL at the tumor site with an APC activator
like IMP321, while releasing the PD-1 brake on TIL,
may lead to greater anti-tumor efficacy than anti-PD-1
agents alone. Synergistic activity of the LAG-3Ig/anti-
PD-1 combination has been shown pre-clinically in hu-
man peripheral blood mononuclear cells (PBMC) from 10
donors stimulated with cytomegalovirus peptides, and in a
CT26wt colon cancer mouse model. The phase I TACTI-
mel (Two ACTive Immunotherapies in Melanoma) trial,
initiated in 2016, is examining the combination IMP321 +
pembrolizumab in unresectable or metastatic melanoma
(NCT02676869).
To treat solid tumors, the laboratory of Prasad S. Adu-
sumilli, MD, FACS, FCCP (Memorial Sloan Kettering
Cancer Center) has chosen mesothelin, a cell-surface
antigen, as a target for CAR T cell therapy. Mesothelin is
expressed in the majority of solid tumors and is associ-
ated with aggressive cancer growth, thus serving as a ra-
tional target [14]. The group demonstrated that regional
delivery of mesothelin-targeted, second-generation CAR
T cells achieved CD4+ T cell-dependent, long-term im-
munity even at a 30-fold lower dose than systemically
delivered CAR T cells [15]. They translated these obser-
vations to two clinical trials. In the first trial
(NCT02414269), mesothelin-targeted CAR T cells were
administered intrapleurally to patients with mesotheli-
oma, lung, or breast cancer with pleural disease, and in
the second trial (NCT02792114), CAR T cells were ad-
ministered systemically to patients with HER-2-negative
metastatic breast cancer. To overcome tumor-mediated
inhibition of CAR T cells, they developed and evaluated
T cell extrinsic (PD-1 blocking antibody) and intrinsic
(co-transduction of CAR T cells with a PD-1 dominant
negative receptor (DNR) or PD-1/4-1BB fusion protein)
strategies to overcome PD-L1/2 inhibition. The addition
of PD-1 blocking agents does potentiate CAR T cell
therapy but multiple administrations are necessary. By
contrast, a single dose of mesothelin-targeted CAR T
cells co-expressing PD-1 DNR restores effector func-
tions, enhances tumor control, and prolongs median sur-
vival [16]. Converting PD-L1 inhibition into a positive
costimulatory signal by PD-1/4-1BB construct co-
transduction into CAR T cells enhanced cytokine secre-
tion and T cell accumulation. These strategies to prolong
the functional persistence of CAR T cells are now being
investigated in clinical trials.
Wrapping up the Pre-Clinical session, Jane Grogan,
PhD (Genentech) presented on the immunoreceptor
TIGIT (T cell immunoreceptor with Ig and ITIM do-
mains), which was originally discovered nearly a decade
ago. An inhibitory receptor found on T cells and NK
cells, TIGIT acts synergistically with the PD-1/PD-L1
axis upon binding to its cognate receptor PVR, which is
expressed on tumor cells or DC [17]. The result of this
interaction serves to limit T cell activity within the TME.
Pre-clinical models of established tumors treated using
combined blockade of both the TIGIT/PVR and PD-1/
PD-L1 axes demonstrate superior rescue of exhausted or
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anergic T cells compared with inhibition of either path-
way alone [18]. TIGIT is thought to regulate anti-tumor
T cell effector responses in a number of different ways.
Due to the presence of its ITIM-like domain, there is
capacity for TIGIT to signal in cis into a cell and shut
down T cell responses, although this has not yet been
shown in primary cells [17, 19–24]. In vivo and in vitro
models have also shown that engagement of PVR by
TIGIT is sufficient to downregulate the production of
inflammatory IL-12 by DC and upregulate TGFβ and IL-
10 production, which could reinforce an immunosup-
pressive TME [17]. Additionally, the relatively higher af-
finity of TIGIT for PVR competes with the lower affinity
activating PVR ligand, CD226, and can replace it in the
synapse, thereby supporting T cell inhibition. Together
with the discovery of high TIGIT expression in the TIL
and peripheral blood of patients with NSCLC, these data
support moving an immunotherapy agent targeting
TIGIT into phase I clinical trials.
Strategic Considerations of Combinations and
Biomarkers in New Agent Development
Combination Immunotherapy Approaches
Although the greater than 800 open trials of immuno-
therapy combinations currently underway [25] might
seem overwhelming, Charles G. Drake, MD, PhD
(Columbia University Herbert Irving Comprehensive
Cancer Center) suggested that this number seemed low
when taking into account all of the combinations pos-
sible. Laying the foundation for the Extended Panel Dis-
cussion which addressed how to prioritize among so
many therapeutic candidates, Dr. Drake highlighted
combinations that are already FDA-approved, before go-
ing on to discuss the possibility of combining immuno-
therapy with conventional approaches, targeting other
cell populations such as myeloid cells, and using im-
mune activators, by way of illustrating the plethora of
possibilities for combination strategies based on cancer
immunotherapy.
To date, combinatorial approaches that have received
FDA approval are limited to combinations of single im-
munotherapeutic agents, such as ipilimumab + nivolu-
mab in the setting of unresectable or metastatic
melanoma [26]. The biological rationale for this strategy
is that the molecules targeted may act on different cell
types within the TME. That is, PD-1 operates at the
junction between the T cell and the tumor cell or APC,
deactivating the T cell. In contrast, CTLA-4 is predom-
inantly expressed by Treg in the TME, where it exerts
contact-dependent suppression. Despite the synergism
predicted by animal models, ipilimumab + nivolumab
has only proven additive in humans. Dr. Drake cau-
tioned that this additive efficacy comes with ipilimumab-
driven additive toxicity [27]. Moreover, this approach
has led investigators to revisit the topic of predictive bio-
markers, since PD-L1 positivity did not correlate with
clinical outcomes. Other attempts to take advantage of
the synergism of combination immunotherapy observed
in animal models have targeted multiple immune check-
points on the same cell, such as PD-1 and LAG-3. T
cells that co-express more than one immune checkpoint
tend to be the least functional, and co-blockade of these
molecules in animal models has resulted in synergistic
effects [28] across multiple combinations of agents, but
this has not yet been shown in humans.
The ways in which conventional chemotherapy affect the
immune system will influence strategies for combining
these drugs with immunotherapy agents. For example,
chemotherapy can result in immunogenic cell death, ac-
companied by release of tumor antigens, destruction of im-
munosuppressive populations including MDSC and M2
macrophages, and acquisition of effector function due to
lymphopenia-induced homeostatic proliferation [29]. One
implication of this is the need to consider timing of drug
administration, as PD-1 blockade may be most important
at the time of antigen encounter (chemotherapy-induced
immunogenic cell death) [30]. When considering combin-
ing immunotherapy with standard cancer treatments, it is
tempting to think first about chemotherapy and radiation.
However, Dr. Drake shared preliminary evidence that more
attention should be paid to other anti-tumor agents, such
as hormonal therapy. Trials of anti-PD-1/PD-L1 monother-
apy in patients with prostate and colorectal cancer did not
lead to encouraging objective responses [31], perhaps owing
to a lack of anti-PD-1/PD-L1 therapy targets in the TME.
Interestingly, investigations of patients with castration re-
sistant prostate cancer that progressed on enzalutamide re-
vealed that enzalutamide resistance is associated with the
expression of PD-1 and PD-L1/2 on antigen presenting
cells [32], and the addition of anti-PD-1 in a small trial of
such patients resulted in durable objective responses as well
as reductions in PSA levels [33]. Another therapeutic that
has yielded exciting results in combination with immuno-
therapy is VEGF inhibition. In one recent study of atezoli-
zumab (anti-PD-L1) + bevacizumab (anti-VEGF) in kidney
cancer, overall response rate was 40% (historical response
rates with atezolizumab and bevacizumab monotherapy are
approximately 15 and 9%, respectively) and a tolerable
safety profile [34]. It is postulated that VEGF blockade may
function in coordination with anti-PD-L1 by normalizing
the tumor vasculature, which would facilitate trafficking of
T cells into the TME [34], although it has also been shown
to promote immunogenic cell death, and generation of sup-
pressive DC and MDSC [35].
Other rational combination approaches seek to ad-
dress the hostile TME. A number of these trials involve
inhibition of indoleamine 2,3-dioxygenase (IDO), an en-
zyme produced by MDSC and dysfunctional DC within
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the TME that leads to generation of Treg, which further
reinforce an immunosuppressive environment [36]. The
population of IL-10-secreting suppressive macrophages
found in tumors appear to be maintained by CSF-1,
which has also become an attractive therapeutic target
[37], primarily in combination with immune checkpoint
blockade. In the case of tumors that are “immunological
deserts” [38] such as prostate cancer, which is typically
poorly infiltrated by T cells, one other approach is to
introduce an agent intratumorally (e.g. talimogene laher-
parepvec, viral constructs, TLR agonists, etc.) that can
activate the TME to make it more visible to the immune
system. Together with immune checkpoint inhibition to
overcome adaptive immune resistance, this approach has
the potential to lead to an abscopal effect by increasing
direct presentation of tumor antigens to T cells at the
site of the primary tumor as well as cross-presentation
in the draining lymph node. This could generate a popu-
lation of activated tumor-specific CD8+ T cells that traf-
fic throughout the body and provide systemic control.
Although the majority of these combination approaches
show promise in animal models, choosing an effective
combination to move into human clinical trials remains
a challenge due to the inherent disparities between ani-
mal models and humans.
Extended Panel Discussion
The multidisciplinary panel, moderated by Dr. Chen,
comprised Dr. Bot, Dr. Dansey, Dr. Drake, Gordon J.
Freeman, PhD (Dana-Farber Cancer Institute), Raj K.
Puri, MD, PhD (U.S. FDA), and Marc Theoret, MD (U.S.
FDA). Dr. Chen opened the discussion by asking panel
members to describe their vision of the future, consider-
ing the large number of combination immunotherapy
approaches currently in clinical trials. The heterogeneity
of malignant diseases along with cost and safety con-
cerns will continue to drive the need for multiple solu-
tions. Contributing to the complexity of this issue is the
fact that there are several different ways to give two
drugs together, a challenge that increases significantly
with the introduction of a third agent. Panel members
uniformly expressed optimism about the influx of poten-
tial new treatment strategies and saw this as an oppor-
tunity to determine which strategies best achieve the
balance of efficacy and safety, and to establish the mech-
anistic basis for efficacy.
To rapidly prioritize among the combination trials and
ensure that only the most promising trials are selected
to move forward, it will be critical to integrate bio-
markers into clinical decision-making. For example, al-
though biomarkers predictive of response to treatment
remain incompletely defined for immunotherapeutics,
there are populations known to be highly responsive to
such treatments, including people with microsatellite
instability, those with PDL1 amplifications, and the pres-
ence of human papillomavirus, Epstein-Barr virus, or the
Merkel cell polyomavirus in patients whose tumors have
a strong viral etiology. Additionally, optimization of the
drug development process and collaboration across dis-
ciplines were identified as opportunities to improve trial
design on the front end of the process.
The recent influx of combination trials would seem to
represent a burden for the FDA, but Dr. Theoret ex-
plained that the current regulatory framework is de-
signed with two approval pathways to help facilitate the
process as efficiently as possible. Agents that demon-
strate substantial evidence of a treatment effect that is
representative of clinical benefit in adequate and well-
controlled clinical trials are evaluated via the regular ap-
proval pathway, which does not require demonstration
of comparative efficacy. In contrast, all four of the FDA
expedited programs, which includes an accelerated ap-
proval pathway, do consider the available therapy.
Intended for therapies that address unmet medical needs
for serious and life-threatening conditions, the expedited
programs are set up to facilitate and expedite the devel-
opment of agents at multiple points in the process.
Conclusions
The concepts and strategies presented at the SITC 2016
New Cancer Immunotherapy Agents in Development
program highlighted creative and elegant approaches in
a rapidly-evolving field. A common thread throughout
all presentations was a need for a deeper understanding
of the mechanisms by which current immunotherapies
exert their effects in order to continue to improve can-
cer outcomes. Mechanistic approaches can then poten-
tially lead to rational combinations of two or more
agents that exert an immunologic effect as well as pro-
vide potential predictive biomarker candidates to help
identify those patients most likely to benefit from a par-
ticular approach. Many presenters also expressed the
opinion that no single agent was likely to be the “magic
bullet” that has been long sought-after in the fight
against cancer; rather, combination approaches that pro-
vide a multi-pronged intervention are expected to yield
the greatest clinical success.
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